ARK Investment Management Trims Position in Twist Bioscience
Recent 13F regulatory filings indicate that ARK Investment Management reduced its holdings in Twist Bioscience Corporation.
Stocks · News reference
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Recent 13F regulatory filings indicate that ARK Investment Management reduced its holdings in Twist Bioscience Corporation.
Multiple financial institutions updated their ratings and price targets for Twist Bioscience on November 14, 2026, with targets ranging from $135 to $175.
Baird analyst Catherine Ramsey Schulte has maintained a Buy rating on Twist Bioscience while increasing the price target from $115 to $135.
Canaccord Genuity has reduced its price target for Twist Bioscience shares from $205 to $150.
Following the company's fiscal fourth-quarter earnings report, Guggenheim and BofA Securities lowered their price targets for Twist Bioscience Corporation.